Physician profile
Phillip D Cox
NPI 1629262944
$20,225.61
in general payments reported to CMS, 2019-2025
42 companies · $1,610 in 2025
The $1,610 reported for 2025 was more than what 84% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,203 · 2020: $1,113 · 2021: $1,433 · 2022: $1,759 · 2023: $7,692 · 2024: $3,415 · 2025: $1,610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,519 · Travel and Lodging: $3,187 · Education: $3,012.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,518.57 |
| Travel and Lodging | $3,186.70 |
| Education | $3,012.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,275.53 | 2023-2025 | Ion, Da Vinci Surgical System |
| Pulmonx Corporation | $3,392.48 | 2022-2024 | Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter |
| Astrazeneca Pharmaceuticals LP | $2,204.18 | 2019-2025 | Fasenra, Breztri, Airsupra |
| Ethicon INC. | $1,675.63 | 2019 | |
| Glaxosmithkline, LLC. | $1,487.46 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $990.59 | 2019-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $920.00 | 2019-2025 | Ofev, Jascayd, Jardiance |
| Novartis Pharmaceuticals Corporation | $694.34 | 2019-2024 | |
| Genzyme Corporation | $599.48 | 2019-2025 | |
| Insmed, INC. | $455.44 | 2019-2025 | Arikayce, Brinsupri |
| Actelion Pharmaceuticals US, INC. | $406.52 | 2019-2024 | Uptravi |
| Genentech USA, INC. | $343.50 | 2019-2024 | Xolair |
| Axsome Therapeutics, INC. | $342.07 | 2022-2025 | Sunosi |
| Jazz Pharmaceuticals INC. | $280.50 | 2019-2022 | |
| Mylan Specialty L.P. | $256.99 | 2019-2023 | Yupelri |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galvanize Therapeutics, INC | $224.39 | 2024-2025 | Aliya System |
| Electromed, INC. | $165.84 | 2019-2025 | Smartvest |
| Verona Pharma, INC. | $163.68 | 2025 | Ohtuvayre |
| Abiomed | $148.40 | 2024 | Impella |
| Amgen INC. | $134.45 | 2022-2024 | Tezspire |
| Pfizer INC. | $119.56 | 2019-2024 | |
| Mallinckrodt Hospital Products INC. | $98.98 | 2020-2024 | Acthar, Terlivaz |
| Merck Sharp & Dohme LLC | $94.00 | 2019-2025 | Capvaxive, Zerbaxa, Dificid |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $86.52 | 2023 | Lifevest |
| Sunovion Pharmaceuticals INC. | $84.77 | 2019 | |
| Advanced Respiratory, INC | $84.18 | 2020-2021 | |
| Harmony Biosciences LLC | $83.98 | 2022-2025 | |
| Grifols USA, LLC | $77.86 | 2024-2025 | Prolastin-C Liquid |
| Abbvie INC. | $58.09 | 2023-2025 | Avycaz |
| Vifor Pharma, INC. | $41.38 | 2024 | Zemaira, Veltassa |
| Sanofi-Aventis U.S. LLC | $35.89 | 2020-2021 | |
| Eisai INC. | $32.66 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $22.50 | 2019 | |
| Mallinckrodt Enterprises LLC | $21.90 | 2019 | |
| Viatris Specialty LLC | $20.24 | 2025 | Yupelri |
| Janssen Pharmaceuticals, INC | $19.14 | 2021 | |
| Xeris Pharmaceuticals, INC. | $18.27 | 2023 | Keveyis |
| United Therapeutics Corporation | $14.88 | 2022 | |
| Alexion Pharmaceuticals, INC. | $14.40 | 2019 | |
| Inogen, INC. | $13.35 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Circassia INC. | $11.17 | 2019 | |
| Erbe USA INC | $10.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phillip Cox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.